Syverson Strege & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.12M Buy
932
+1
+0.1% +$1.02K 0.24% 42
2026
Q1
$856K Sell
931
-20
-2% -$20.3K 0.21% 50
2025
Q4
$1.02M Sell
951
-75
-7% -$71.7K 0.24% 43
2025
Q3
$783K Sell
1,026
-763
-43% -$568K 0.19% 55
2025
Q2
$1.39M Buy
1,789
+1,352
+309% +$1.05M 0.33% 33
2025
Q1
$361K Buy
437
+22
+5% +$18.3K 0.12% 56
2024
Q4
$320K Buy
+415
New +$344K 0.11% 57
2024
Q3
– Sell
-473
Closed -$428K – 73
2024
Q2
$428K Buy
473
+136
+40% +$109K 0.15% 47
2024
Q1
$262K Buy
+337
New +$240K 0.09% 59
2023
Q2
– Sell
-414
Closed -$142K – 376
2023
Q1
$142K Buy
414
+84
+25% +$28.3K 0.06% 72
2022
Q4
$121K Hold
330
– – 0.05% 82
2022
Q3
$107K Hold
330
– – 0.05% 85
2022
Q2
$107K Hold
330
– – 0.04% 98
2022
Q1
$95K Hold
330
– – 0.1% 92
2021
Q4
$91K Sell
330
-120
-27% -$30.4K 0.07% 100
2021
Q3
$104K Buy
450
+120
+36% +$29.6K 0.08% 96
2021
Q2
$76K Hold
330
– – 0.07% 103
2021
Q1
$62K Hold
330
– – 0.06% 106
2020
Q4
$56K Buy
+330
New +$49.3K 0.05% 106

Other funds holding LLY

Syverson Strege & Co's LLY Position: Q2 2026 in Review

Syverson Strege & Co increased its Eli Lilly (LLY) stake by 0.11% in Q2 2026, buying an estimated $1.02K and bringing the position to 932 shares worth $1.12M. The position accounts for 0.24% of the portfolio, ranked #42.

Syverson Strege & Co first reported a position in LLY in Q4 2020 and has held it in 19 quarters since. The position peaked at $1.39M in Q2 2025. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Syverson Strege & Co held 932 shares of Eli Lilly worth $1.12M as of Q2 2026.
  • Syverson Strege & Co bought 1 Eli Lilly share in Q2 2026, an estimated $1.02K.
  • Eli Lilly made up 0.24% of Syverson Strege & Co's portfolio in Q2 2026, its #42 holding.
  • Syverson Strege & Co first reported a position in Eli Lilly in Q4 2020 and has held it in 19 quarters since.
  • Syverson Strege & Co's Eli Lilly position peaked at $1.39M in Q2 2025.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Syverson Strege & Co's 13F filing for Q2 2026, filed 6 Aug 2026.